What is euglycemic diabetic ketoacidosis (euglycemic DKA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Euglycemic Diabetic Ketoacidosis (Euglycemic DKA)?

Euglycemic DKA is a life-threatening variant of diabetic ketoacidosis characterized by metabolic acidosis, ketonemia, and blood glucose levels below 250 mg/dL—critically, the absence of marked hyperglycemia makes this diagnosis easily missed and delays treatment. 1, 2, 3

Key Diagnostic Features

Euglycemic DKA presents with the same metabolic derangements as classic DKA but with unexpectedly low glucose levels (typically <250 mg/dL, sometimes even normal). The diagnostic triad includes:

  • Metabolic acidosis: pH <7.3, bicarbonate <15-18 mEq/L
  • Ketonemia/ketonuria: Elevated β-hydroxybutyrate (preferred test) or positive ketones
  • Blood glucose <250 mg/dL (often 100-200 mg/dL range) 4, 5, 6

The anion gap is elevated (>10-12), confirming high anion gap metabolic acidosis 7.

Primary Causes and Risk Factors

SGLT-2 Inhibitors (Most Common Modern Cause)

The widespread use of SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) has dramatically increased euglycemic DKA incidence 4, 8, 5. These medications:

  • Cause urinary glucose loss, preventing hyperglycemia
  • Create a baseline state of mild ketonemia
  • Lower the threshold for ketoacidosis development
  • Can trigger euglycemic DKA within 48-72 hours of initiation or after prolonged use 9, 10

Other Precipitating Factors

  • Ketogenic/low-carbohydrate diets: Severe carbohydrate restriction combined with insulin deficiency 11, 9
  • Pregnancy: Particularly in gestational or pre-existing diabetes 6, 12
  • Starvation/reduced oral intake: Any cause of prolonged fasting 6
  • Acute illness/infection: Sepsis, influenza, surgical stress 8, 9, 13
  • Insulin pump failure 6
  • Bariatric surgery, gastroparesis, chronic liver disease 6

Pathophysiology

The mechanism involves:

  1. Relative insulin deficiency (milder than classic DKA) coupled with elevated counterregulatory hormones
  2. Carbohydrate deficit (from SGLT-2 inhibitor glycosuria, dietary restriction, or reduced intake)
  3. Increased glucagon/insulin ratio driving lipolysis and ketogenesis
  4. Prevention of hyperglycemia by ongoing glucose loss (SGLT-2 inhibitors) or lack of substrate 4, 6

Clinical Presentation

Symptoms (Non-specific and Easily Missed)

  • Nausea, vomiting, abdominal pain
  • Malaise, fatigue, weakness
  • Polyuria (may be present)
  • Kussmaul respirations (deep, labored breathing from acidosis)
  • Altered mental status (less common than in hyperglycemic DKA) 7, 12

Critical Diagnostic Pitfall

The normal or mildly elevated glucose misleads clinicians into dismissing DKA, causing dangerous delays. Always check blood ketones (β-hydroxybutyrate preferred) and arterial/venous blood gas in any diabetic patient with unexplained metabolic symptoms, regardless of glucose level 5, 6, 12.

Why This Matters for Morbidity and Mortality

Delayed diagnosis leads to:

  • Prolonged severe acidosis (pH <7.0 possible)
  • Electrolyte derangements (hypokalemia, hypophosphatemia)
  • Cardiac arrhythmias and respiratory depression
  • Cerebral edema risk (though less than hyperglycemic DKA)
  • Higher mortality if untreated 6

The half-life of SGLT-2 inhibitors (12-24 hours) means euglycemic DKA may be more prolonged than classic DKA, requiring extended treatment 4.

Treatment Approach (Modified from Classic DKA)

Immediate Management

  1. Start dextrose-containing IV fluids immediately (5-10% dextrose in normal saline)—this is the key difference from hyperglycemic DKA management 4, 11, 6
  2. Delay insulin infusion until glucose rises above 250 mg/dL if patient presents with glucose <200 mg/dL 11
  3. If glucose >200 mg/dL: Begin standard insulin infusion (0.1 units/kg/hour) with dextrose-containing fluids 1

Rationale for Dextrose

  • Provides substrate to suppress ketogenesis
  • Stimulates endogenous insulin secretion
  • Prevents hypoglycemia during insulin therapy
  • Corrects the carbohydrate deficit driving ketosis 4, 6

Monitoring

  • β-hydroxybutyrate levels (not urine ketones—nitroprusside method misses β-hydroxybutyrate and shows false worsening as it converts to acetoacetate) 14, 7
  • Anion gap and venous pH every 2-4 hours
  • Electrolytes (especially potassium, phosphate)
  • Blood glucose every 1-2 hours 5

Resolution Criteria

  • Anion gap normalized (<12)
  • pH >7.3
  • Bicarbonate ≥18 mEq/L
  • Ketones cleared (β-hydroxybutyrate <0.6 mmol/L) 14, 5

Transition to Subcutaneous Insulin

Slower transition than classic DKA—continue IV insulin 2-4 hours after subcutaneous basal insulin given to prevent rebound ketoacidosis 1, 2, 5. The prolonged SGLT-2 inhibitor effect necessitates this caution.

Prevention Strategies

For Patients on SGLT-2 Inhibitors

  1. Discontinue SGLT-2 inhibitors 3-4 days before surgery 1
  2. Sick-day rules: Stop SGLT-2 inhibitor during acute illness, fasting, or reduced oral intake 8, 9
  3. Avoid ketogenic diets while on SGLT-2 inhibitors 11, 9
  4. Early follow-up after initiation (within 1-2 weeks) for treatment-naive patients 10

High-Risk Situations Requiring SGLT-2 Inhibitor Cessation

  • Major surgery or procedures
  • Acute infection/sepsis
  • Prolonged fasting (>12-24 hours)
  • Gastrointestinal illness with vomiting/diarrhea
  • Pregnancy 8, 9, 13

Key Clinical Pearls

  • Think euglycemic DKA in any diabetic patient with metabolic acidosis and elevated anion gap, regardless of glucose level
  • SGLT-2 inhibitor use is the most important historical clue in modern practice 5, 12
  • Blood ketone testing (β-hydroxybutyrate) is essential—urine ketones alone are inadequate 14, 12
  • Dextrose-containing fluids are mandatory from the start—this is non-negotiable and distinguishes treatment from classic DKA 4, 11, 6
  • Insulin requirements are often surprisingly low compared to hyperglycemic DKA 9, 10
  • Consider reassessing diabetes phenotype when insulin needs are minimal despite severe ketoacidosis—may indicate preserved beta-cell function 9

References

Research

Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors.

BMJ open diabetes research & care, 2023

Research

Euglycemic diabetic ketoacidosis: A missed diagnosis.

World journal of diabetes, 2021

Research

Euglycemic Diabetic Ketoacidosis: Clinical Suspicion and Diagnosis.

Clinical medicine insights. Endocrinology and diabetes, 2026

Research

A Case of Euglycemic Diabetic Ketoacidosis in a Patient with Diabetic Foot Syndrome.

The international journal of lower extremity wounds, 2025

Guideline

hyperglycemic crises in diabetes.

Diabetes Care, 2004

Related Questions

How is euglycemic ketoacidosis diagnosed and managed?
How should euglycemic ketoacidosis be managed?
In euglycemic diabetic ketoacidosis, should 10% dextrose in water (D10W) or dextrose‑normal saline (DNS) be used as the appropriate IV solution?
What are the primary differences in management between euglycemic ketoacidosis and alcoholic ketoacidosis?
Should a 52-year-old woman with type 2 diabetes who was admitted for diabetic ketoacidosis, now has a closed anion gap, and is on metformin 850 mg twice daily plus basal insulin glargine 10 units daily, have her metformin dose increased, continue the current insulin regimen, or add a thiazolidinedione?
Is it safe to use Vistaril (hydroxyzine) in a patient with supraventricular tachycardia (SVT)?
What is the safest first step in managing a patient who develops supraventricular tachycardia (SVT) while taking buspirone (Buspar)?
What is the interpretation and recommended management for a patient with a 2‑hour oral glucose tolerance test showing fasting glucose 108 mg/dL and 2‑hour glucose 191 mg/dL?
Can buspirone (Buspar) cause supraventricular tachycardia (SVT)?
For a 2‑year‑7‑month‑old child (10.7 kg) with well‑controlled asthma on beclomethasone dipropionate (Clenil 50 µg) twice daily, who is receiving oral acetylcysteine 3.5 mL twice daily, is nebulized acetylcysteine safe or does it risk bronchospasm, and how should it be administered if used?
How should ipratropium bromide nebulizer solution be administered, including dosage and frequency, for adults and children?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.